• KOL
    • KOLs Community
    • Chronic
    • Chronic Hepatitis
    • Patrick Marcellin
    • Patrick Marcellin

      Patrick Marcellin

      Hôpital Beaujon, Clichy, University of Paris, Paris, France | Hepatology Department, Hôpital Beaujon, APHP, INSERM, University of Paris, 92110 Clichy, France;, ...



      KOL Resume for Patrick Marcellin


      Hôpital Beaujon, Clichy, University of Paris, Paris, France


      Centre de recherche sur l'inflammation, Université́ de Paris, Inserm U1149, CNRS ERL8252, Paris, France.

      Hôpital Beaujon, University of Paris, Clichy, France


      CRI, UMR 1149, Inserm, University Paris Diderot, Sorbonne Paris Cité, Paris, France


      Viral Hepatitis Research Unit, Hôpital Beaujon, Clichy, France


      Hôpital Beaujon, University Paris-Diderot, Clichy, France


      Service d'hépatologie, INSERM CRI, Université Paris-Diderot, Clichy, France.

      UMR1149, Team “Physiopathologie et traitements des hépatites virales”, Centre de Recherche sur l’Inflammation, Paris, France


      AP‐HP Beaujon Hospital University Paris Diderot and INSERM UMR1149 Centre de Recherche sur l'inflammation Labex INFLAMEX Hepatology Department Clichy France


      INSERM UMR‐1149 University Denis Diderot Paris 7 PRES Sorbonne Paris Cité Team Physiopathology and Treatment of Viral Hepatitis Centre de Recherche sur l'Inflammation Laboratory of Excellence Labex INFLAMEX Paris France

      Department of Hepatology, Hôpital Beaujon, AP-HP

      Hepatology, Hôpial Beaujon, Clichy


      Department of Hepatology, Beaujon Hospital, AP-HP, Clichy, France



      Patrick Marcellin: Influence Statistics

      Sample of concepts for which Patrick Marcellin is among the top experts in the world.
      Concept World rank
      copies 98 #1
      hbvdna pcr #1
      treatment adv #1
      immunosorbent interferon #1
      hepatitis standard #1
      blv monotherapy patients #1
      combination pegifnα2a #1
      serum aminotransferases cryoglobulin #1
      48 weeks monotherapy #1
      peginterferon alfa rbv #1
      patients genotype non1 #1
      intraportal lymphoid #1
      hcvrna log10 iu #1
      blv chd #1
      2a study daclatasvir #1
      peginterferon hepatitis virus #1
      ifnγ1b week #1
      steatosis year #1
      hemophilia kidney disease #1
      success rate performance #1
      hepather anrs co22 #1
      therapy minority #1
      ifnγ1b alpha interferon #1
      anrs hc16 gammatri #1
      alanine chronic humans #1
      ifi35 mir99a #1
      sofosbuvir daclatasvir ribavirin #1
      supernatant hcv rna #1
      chc subgroup analyses #1
      treated peginterferon #1
      hbsag clearance patients #1
      retreatment peginterferon #1
      future hepatitis virus #1
      disappearance hbeag #1
      assays 22 patients #1
      12 patients hbsag #1
      liver tests abnormality #1
      majority retrospective analysis #1
      chb management #1
      hepatic hepatitis #1
      tma positive genotype #1
      hbsag loss response #1
      minimal fibrosis f1 #1
      peginterferonalpha2a ribavirin #1
      48 72 weeks #1
      ± lamivudine #1
      reduction mir122 #1
      liver hbv hbeag #1
      rvr hcv #1
      fibrosis progression response #1


      Prominent publications by Patrick Marcellin

      KOL-Index: 23867

      BACKGROUND: The novel prodrug tenofovir alafenamide delivers the nucleotide reverse transcriptase inhibitor tenofovir to target cells more efficiently at a lower dose than tenofovir disoproxil fumarate, thereby reducing systemic exposure. We compared the efficacy and safety of the two drugs in patients with HBeAg-negative chronic hepatitis B virus (HBV) infection in a non-inferiority study.

      METHODS: In this ongoing randomised, double-blind, phase 3, non-inferiority study in 105 centres ...

      Known for Disoproxil Fumarate | Tenofovir Alafenamide | Negative Chronic | Patients Hbv Infection | Hbv Dna
      KOL-Index: 23509

      BACKGROUND: Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens were the standard of care in patients with hepatitis C virus (HCV) infection, but the sustained virological response can be suboptimum in patients with HCV genotype 1 infection. The efficacy, safety, and tolerability of the combination of simeprevir, a one-pill, once-daily, oral HCV NS3/4A protease inhibitor versus placebo, plus peginterferon alfa 2a or 2b plus ribavirin was assessed in treatment-naive ...

      Known for Genotype 1 | Simeprevir Placebo | 3 Trial | Peginterferon Alfa Ribavirin | Chronic Heterocyclic Compounds
      KOL-Index: 22852

      BACKGROUND: Only 15-20% of patients with chronic hepatitis C achieve a sustained virological response with interferon therapy. The aim of this study was to compare the efficacy and safety of interferon alpha2b in combination with oral ribavirin with interferon alone, for treatment of chronic infection with hepatitis C virus (HCV).

      METHODS: 832 patients aged 18 years or more with chronic HCV who had not been treated with interferon or ribavirin, were enrolled and randomly allocated one of ...

      Known for 48 Weeks | Interferon Α2b | Randomised Trial | Combination Regimen | Patients Chronic Hepatitis
      KOL-Index: 22067

      BACKGROUND: Hepatitis C virus (HCV) genotype 4 accounts for about 13% of global HCV infections. Because interferon-containing treatments for genotype 4 infection have low efficacy and poor tolerability, an unmet need exists for effective all-oral regimens. We examined the efficacy and safety of an all-oral interferon-free regimen of ombitasvir, an NS5A inhibitor, and paritaprevir (ABT-450), an NS3/4A protease inhibitor dosed with ritonavir (ombitasvir plus paritaprevir plus ritonavir), ...

      Known for Genotype 4 | Paritaprevir Ritonavir | Ribavirin Patients | Treatment Svr12 | 12 Weeks
      KOL-Index: 21070

      BACKGROUND: Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) polymerase.

      METHODS: In two double-blind, phase 3 studies, we randomly assigned patients with hepatitis B e antigen (HBeAg)-negative or HBeAg-positive chronic HBV infection to receive tenofovir DF or adefovir dipivoxil (ratio, 2:1) once daily for 48 weeks. The primary efficacy end point was a plasma HBV DNA ...

      Known for Adefovir Dipivoxil | Chronic Hepatitis | Patients Tenofovir | Viral Suppression | 400 Copies
      KOL-Index: 19968

      BACKGROUND: An unmet need exists for interferon-free and ribavirin-free treatments for chronic hepatitis C virus (HCV) infection. In this study, we assessed all-oral therapy with daclatasvir (NS5A replication complex inhibitor) plus asunaprevir (NS3 protease inhibitor) in patients with genotype 1b infection, including those with high unmet needs or cirrhosis, or both.

      METHODS: We did this phase 3, multicohort study (HALLMARK-DUAL) at 116 sites in 18 countries between May 11, 2012, and ...

      Known for Daclatasvir Asunaprevir | Genotype 1b | 12 Weeks | Treatment Naive | Ineligible Intolerant
      KOL-Index: 19585

      Pegylated interferon alfa-2a (PEG-IFN) may induce sustained virological response (SVR) in 20% of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. In addition, loss of hepatitis B surface antigen (HBsAg) is achieved with a 10% yearly rate after treatment cessation in sustained responders. The aim of this study was to assess on-treatment serum HBsAg kinetics to predict SVR in HBeAg-negative patients treated with PEG-IFN. Forty-eight consecutive patients were ...

      Known for Serum Hbsag | Sustained Virological Response | Patients Svr | Strong Predictor | Treatment Weeks
      KOL-Index: 19213

      BACKGROUND & AIMS: It is unclear whether the magnitude of reduction in hepatitis C virus (HCV) RNA between baseline and week 4 of treatment influences the probability of achieving a sustained virological response (SVR) in patients without a week 4 rapid virological response (RVR).

      METHODS: Data were retrospectively analyzed from two studies in which treatment-naive patients received peginterferon alfa-2a (40KD) 180 μg/week plus ribavirin 1000/1200 mg/day for 48 weeks. Five hundred and ...

      Known for Week 4 Response | 1 Patients | Hcv Rna | Rvr Svr | Studies Ribavirin
      KOL-Index: 18528

      The objective was to determine the proportion of patients with chronic hepatitis B in whom hepatitis B virus DNA is demonstrated by polymerase chain reaction after HBeAg to anti-HBe or HBsAg to anti-HBs spontaneous or therapeutically induced seroconversion. Polymerase chain reaction was performed on serum 6 and 12 mo after HBeAg to anti-HBe seroconversion in 12 patients and 2, 6 and 12 mo after HBsAg to anti-HBs seroconversion in 13 patients. Polymerase chain reaction was performed on ...

      Known for Polymerase Chain Reaction | Virus Dna | Patients Hbsag | Antigens Hepatitis | Hbeag Anti
      KOL-Index: 17342

      BACKGROUND: In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are suboptimal. Boceprevir, a protease inhibitor that binds to the HCV nonstructural 3 (NS3) active site, has been suggested as an additional treatment.

      METHODS: To assess the effect of the combination of boceprevir and peginterferon-ribavirin for retreatment of patients with chronic HCV genotype 1 ...

      Known for 1 Infection | Hcv Genotype | Boceprevir Peginterferon | Treated Chronic | Sustained Virologic Response
      KOL-Index: 17242

      Approximately one third of hepatitis C virus (HCV) genotype 1 patients achieved a sustained virological response (SVR) after 24 weeks of treatment with peginterferon alpha-2a (40 kd) plus ribavirin in a randomized, multinational trial. We aimed to identify factors associated with a rapid virological response (RVR) at week 4 (HCV RNA <50 IU/mL) and a SVR (HCV RNA <50 IU/mL at the end of follow-up) in these patients. Stepwise multiple logistic regression analysis was used to explore the ...

      Known for 24 Weeks | 1 Patients | Hcv Genotype | Early Identification | Svr Rvr
      KOL-Index: 17181

      OBJECTIVE: Hepatitis B e antigen (HBeAg) seroconversion and hepatitis B surface antigen (HBsAg) loss are important clinical outcomes for patients with chronic hepatitis B (CHB) treated with antiviral therapy. To date, there have been few studies that have evaluated viral sequence markers predicting serological response to nucleos(t)ide analogue (NA) treatment.

      DESIGN: We used next-generation sequencing (NGS) and quantitative HBV serology (HBeAg and HBsAg) to identify viral sequence ...

      Known for Hbsag Loss | Chronic Hepatitis | Deep Sequencing | Basal Core Promoter | Functional Cure

      Key People For Chronic Hepatitis

      Top KOLs in the world
      Patrick Marcellin
      chronic hepatitis adefovir dipivoxil hcv genotype
      Michael Peter Manns
      chronic hepatitis liver transplantation hepatocellular carcinoma
      Anna Shuk‐Fong Lok
      chronic hepatitis hepatocellular carcinoma united states
      Stefan S Zeuzem
      chronic hepatitis hcv genotype liver fibrosis
      Jay H Hoofnagle¶¶
      chronic hepatitis liver injury united states
      Zachary D Goodman
      chronic hepatitis liver fibrosis hepatocellular carcinoma

      Patrick Marcellin:Expert Impact

      Concepts for whichPatrick Marcellinhas direct influence:Chronic hepatitis,  Patients chronic hepatitis,  Adefovir dipivoxil,  Hepatitis virus,  Hcv genotype,  Pegylated interferon,  Hepatitis chronic,  Liver fibrosis.

      Patrick Marcellin:KOL impact

      Concepts related to the work of other authors for whichfor which Patrick Marcellin has influence:Chronic hepatitis,  Liver fibrosis,  Hepatocellular carcinoma,  Hcv infection,  Antiviral therapy,  Pegylated interferon,  Transient elastography.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Hôpital Beaujon, Clichy, University of Paris, Paris, France | Hepatology Department, Hôpital Beaujon, APHP, INSERM, University of Paris, 92110 Clichy, France;, | Centre de recherche sur l'inflammation, Université́ de Paris,

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.